Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock

Key Points

• Royalty Pharma EVP Marshall Urist sold 4,126 shares at an average price of $57.88, totaling approximately $238,813. The Rule 10b5-1 transaction cut his ownership by 50%, leaving him with 4,126 shares.
• Royalty Pharma shares recently traded near $58.36, with a market capitalization of about $33.56 billion and a 1-year range of $35.23 to $64.38. The company reported quarterly EPS of $1.32, exceeding estimates, though revenue fell short of expectations.
• The company pays a quarterly dividend of $0.235 per share, or $0.94 annually, representing a 1.6% yield. Analysts maintain a consensus “Buy” rating with an average price target of $61.29, while institutional investors own 54.35% of shares.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 4,126 shares of the company's stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $57.88, for a total value of $238,812.88. Following the transaction, the executive vice president owned 4,126 shares of the company's stock, valued at approximately $238,812.88. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock traded up $0.14 during midday trading on Wednesday, hitting $58.36. The company had a trading volume of 3,652,814 shares, compared to its average volume of 3,444,227. The business's 50 day simple moving average is $59.59 and its two-hundred day simple moving average is $54.71. The stock has a market cap of $33.56 billion, a PE ratio of 40.25, a P/E/G ratio of 1.38 and a beta of 0.44. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma PLC has a 1-year low of $35.23 and a 1-year high of $64.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.27 by $0.05. The firm had revenue of $674.14 million during the quarter, compared to analysts' expectations of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. As a group, equities analysts predict that Royalty Pharma PLC will post 5.32 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were given a dividend of $0.2350 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma's dividend payout ratio is currently 64.83%.

Institutional Investors Weigh In On Royalty Pharma

A number of hedge funds have recently made changes to their positions in RPRX. Phillips Wealth Planners LLC grew its stake in Royalty Pharma by 1.9% during the fourth quarter. Phillips Wealth Planners LLC now owns 13,113 shares of the biopharmaceutical company's stock worth $521,000 after buying an additional 242 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Royalty Pharma by 3.4% in the 1st quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company's stock worth $375,000 after acquiring an additional 254 shares in the last quarter. Bessemer Group Inc. grew its position in Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 282 shares during the last quarter. CoreCap Advisors LLC increased its holdings in Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 413 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 437 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings raised Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. The Goldman Sachs Group reiterated a "buy" rating and set a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Morgan Stanley restated an "overweight" rating and issued a $65.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Bank of America reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Finally, Wall Street Zen cut shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus price target of $61.29.

Royalty Pharma Company Profile

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.